QL-RT-20

Overview

This 20mg vial of Retatrutide (LY3437943) is intended for extended research protocols requiring higher-dose titration or multi-point receptor saturation studies. Same lyophilized formulation as the 10mg variant -- double the concentration per vial, reducing the number of vials needed for longer study timelines.

Primary Research Areas

• Dose-response profiling -- higher-dose kinetics for GIP/GLP-1/glucagon concurrent agonism, including receptor saturation curves and EC50 determination
• Extended protocols -- research requiring consistent compound supply across longer study timelines without batch-to-batch variability
• Receptor occupancy studies -- saturation binding at all three target receptors and competitive displacement assays
• Comparative pharmacology -- side-by-side studies with dual agonists at equivalent molar doses to isolate glucagon receptor contribution
• Chronic administration models -- multi-week protocols studying sustained metabolic effects and receptor desensitization kinetics